Percutaneous Electrical Nerve Stimulationand Percutaneous Neuromodulation Therapy
Defines Premera Bluecross coverage position for percutaneous electrical neurostimulation (PENS) and percutaneous neuromodulation therapy (PNT) for chronic pain conditions, summarizes evidence, coding guidance, related guidance and Medicare NCD applicability. Applies to commercial lines (not Medicare Advantage).
Policy renumbered from 7.01.29 to 7.01.588 on 10/01/23; annual reviews through 01/22/2026 with policy statements unchanged.
Coverage Summary & Determination
Defines Premera Blue Cross coverage position for Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT) for chronic pain conditions. Both procedures are designated investigational and therefore not covered for the treatment of chronic pain in the commercial lines population. This policy applies to commercial lines (does not apply to Medicare Advantage).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.